SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Kilitch Drugs skyrockets on reporting seven-fold rise in consolidated FY12 net profit

15 May 2012 Evaluate

Kilitch Drugs (India) is currently trading at Rs. 53.40, up by 2.65 points or 5.22% from its previous closing of Rs. 50.75 on the BSE.

The scrip opened at Rs. 60.00 and has touched a high and low of Rs. 60.00 and Rs. 53.40 respectively. So far 310 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 88.40 on 08-Sep-2011 and a 52 week low of Rs. 40.05 on 07-Jan-2012.

Last one week high and low of the scrip stood at Rs. 60.00 and Rs. 50.05 respectively. The current market cap of the company is Rs. 71.45 crore.

The promoters holding in the company stood at 64.43% while Institutions and Non-Institutions held 0.01% and 35.56% respectively.

Kilitch Drugs India has reported a fall of 10.94% in its net profit at Rs 78.92 crore for the quarter ended March 31, 2012 as compared to Rs 88.62 crore for the same quarter in the previous year.  Total income has decreased by 84.66% at Rs 16.39 crore for quarter under review as compared Rs 106.82 crore for the quarter ended March 31, 2011.

For the full year ended March 31, 2012, on the consolidated basis, the company has posted a rise of 729.87% in its net profit at Rs 86.97 crore for the year ended March 31, 2012 as compared to Rs 10.48 crore for the same period in the previous year. However, total income has decreased by 25.63% at Rs 108.80 crore for year under review as compared to Rs 146.30 crore for the period ended March 31, 2011.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×